Plasticity of Drug-Naïve and Vemurafenib- or Trametinib-Resistant Melanoma Cells in Execution of Differentiation/Pigmentation Program
MITF-M level is changed in melanoma cells after development of resistance to vemurafenib (PLX) or trametinib (TRA). (a) MITF-M expression at the transcript level. qRT-PCR data are normalized to the expression of a reference gene RPS17. Data represent mean values ± SD. Statistically significant differences are indicated: p<0.05. (b) MITF-M protein level assessed by immunoblotting. β-actin was used as loading control. The proteins were visualized on a medical X-ray film. (c) MITF-positive cells are shown as representative density plots and bars representing percentages of MITF-positive cells in drug-naïve and their respective resistant cell populations. Data are presented as mean ± SD. Statistically significant differences are indicated: p<0.05. (d) MITF expression in tumour specimens collected from patients before treatment and post-relapse with resistance developed either to vemurafenib or to combined treatment, dabrafenib and trametinib. Results are shown as log2 ratios normalized to the mean intensity of pretreatment specimens. Data were obtained from NCBI GEO (http://www.ncbi.nlm.nih.gov/geo/). Accession numbers are indicated.
We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.